A Phase 2 interventional study of Modzatinib and Placebo in Lichen Planus, sponsored by Aclaris Therapeutics, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Aclaris Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Lichen Planus with a site in United States — 7 open to participants now, 8 under way, 1 of them phase 3. Lichen Planus · United States.
Among the 34 studies in Lichen Planus with a site in United States, this one is the 6th largest by planned enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2026, is one of 18 in phase 2, and was the 34th registered.
75 studies on the registry are indexed under Lichen Planus; 16 are open to participants now.
Browse Lichen Planus studies →7 of the 34 studies in Lichen Planus with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Australia, Canada and 1 more country
Ages 18–99
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Priovant Therapeutics, Inc. · Sites in United States, Australia, Canada and 1 more country
Ages 18+
The Skin Center Dermatology Group · Sites in United States
Ages 18+
Henry Ford Health System · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Lichen Planus studies recruiting now, 6 (46%) set no upper age limit and 4 (31%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 19 · Phase 3 1 · Phase 4 2
First in 1996; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 102 is above the median of 30 across 56 interventional studies indexed under Lichen Planus.
Median enrollment 24 across the 27 interventional studies, 80 across the 7 observational. Of the 23 that completed or were terminated, 12 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 34 have an industry lead sponsor. The 10 most frequent:
Aclaris Therapeutics, Inc. is the lead sponsor of 34 studies on the registry; 1 is open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 22 (88%) have results posted.
Aclaris Therapeutics, Inc. has 1 study filed under Lichen Planus — fewer than ten, so there is no comparison to draw.
4 of the studies in Lichen Planus with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07487948Icahn School of Medicine at Mount SinaiSafety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris | 2027-04-05 |
| NCT00542373M.D. Anderson Cancer CenterWidefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer | 2027-04-30 |
| NCT06472765Vaginal Biome ScienceVaginal Ecosystem and Network in the United States Study | 2027-05-15 |
| NCT07396168The Skin Center Dermatology GroupNemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study. | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 34 studies in Lichen Planus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates modzatinib versus placebo in participants with biopsy-proven forms of moderate-to-severe lichen planus (LP).
Key Inclusion Criteria:
Specific criteria for each subtype below:
Key Exclusion Criteria:
Note: Other protocol-defined inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive modzatinib or placebo administered orally twice daily (BID) for 16 weeks.
Drug: Modzatinib · Drug: Placebo
Participants will receive modzatinib or placebo administered orally BID for 16 weeks.
Drug: Modzatinib · Drug: Placebo
Participants will receive modzatinib or placebo administered orally BID for 24 weeks.
Drug: Modzatinib · Drug: Placebo
Oral tablets
Also known as: ATI-2138
Oral tablets
Participants With OLP: Change From Baseline in Activity Score of the Oral Disease Severity Score (ODSS) at Week 16
Time frame: Baseline, Week 16
Participants With CLP: Change From Baseline in Modified Lichen Planus Area and Severity Index (LPASI) Score at Week 16
Time frame: Baseline, Week 16
Participants With LPP: Change From Baseline in Lichen Planopilaris Activity Index (LPPAI) Score at Week 24
Time frame: Baseline, Week 24
Percentage of Participants With Investigator Global Assessment (IGA) Score of 0 or 1 and at Least a 2-point Improvement Over Time
Time frame: Baseline up to Week 26
Participants With OLP: Change From Baseline in Activity Score of the ODSS Over Time
Time frame: Baseline, up to Week 18
Participants With OLP: Change From Baseline in Total ODSS Over Time
Time frame: Baseline, up to Week 18
Participants With OLP: Change From Baseline in Total Reticulation Erythema and Ulceration (REU) Score Over Time
Time frame: Baseline, up to Week 18
Participants With OLP: Change From Baseline in Weekly Average of Daily Worst Pain Numeric Rating Scale (NRS) Scores Over Time
Time frame: Baseline, up to Week 18
Participants With OLP: Change From Baseline in Weekly Average of Daily Worst Burning Sensation NRS Scores Over Time
Time frame: Baseline, up to Week 18
Participants With CLP: Change From Baseline in Modified LPASI Score Over Time
Time frame: Baseline, up to Week 18
Participants With CLP: Change From Baseline in Weekly Average of Daily Worst Itch NRS Scores Over Time
Time frame: Baseline, up to Week 18
Participants With LPP: Change From Baseline in LPPAI Score Over Time
Time frame: Baseline, up to Week 26
Participants With LPP: Change From Baseline in Activity Score Over Time
Activity score represents the sum of the 3 severity signs from the LPPAI \* body surface area (BSA).
Time frame: Baseline, up to Week 26
Participants With LPP: Change From Baseline in Weekly Average of Daily Worst Itch NRS Scores Over Time
Time frame: Baseline, up to Week 26
Participants With LPP: Change From Baseline in Weekly Average of Daily Worst Pain NRS Scores Over Time
Time frame: Baseline, up to Week 26
Participants With LPP: Change From Baseline in Weekly Average of Daily Worst Burning Sensation NRS Scores Over Time
Time frame: Baseline, up to Week 26
Participants With LPP: Change From Baseline in Trichoscopy Parameters: Number of Hairs Over Time
Time frame: Baseline, up to Week 26
Participants With LPP: Change From Baseline in Trichoscopy Parameters: Hair Diameter Over Time
Time frame: Baseline, up to Week 26
Participants With LPP: Change From Baseline in Trichoscopy Parameters: Hair Density Over Time
Time frame: Baseline, up to Week 26
Percentage of Participants in Each Category of Patient Global Impression of Change (PGIC) Over Time
Time frame: Baseline up to Week 26
Participants With OLP: Change From Baseline in OLP Symptom Severity Measure (OLPSSM) Total Score Over Time
Time frame: Baseline, up to Week 18
Participants With OLP: Change From Baseline in Oral Health Impact Profile (OHIP)-14 Total Score Over Time
Time frame: Baseline, up to Week 18
Participants With CLP and LPP: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score Over Time
Time frame: Baseline, up to Week 18 (for CLP) and Week 26 (for LPP)
Participants With CLP and LPP: Percentage of Participants With 4-point Improvement or Greater From Baseline in DLQI Total Score Over Time
Time frame: Baseline up to Week 18 (for CLP) and Week 26 (for LPP)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Baseline up to Week 18 (for OLP and CLP) and Week 26 (for LPP)
Peak Concentration of Modzatinib
Time frame: Baseline up to Week 16 (for OLP and CLP) and Week 24 (for LPP)
Trough Concentration of Modzatinib
Time frame: Baseline up to Week 16 (for OLP and CLP) and Week 24 (for LPP)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Mar 2029, 28 months later.
Of 16 phase 2 interventional studies under Lichen Planus, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's planned 28 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.